Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

CIDP Assessment Tools: Grip Strength

Jeffrey A. Allen, MD

University of Minnesota

01:52 MIN

CIDP

Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN

CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

DOWNLOAD PDF

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

15:31 MIN

CIDP

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

DOWNLOAD PDF

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Claudia Sommer, MD

University of Würzburg, Würzburg, Germany

9:35 MIN

CIDP
MMN

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

DOWNLOAD PDF

NOW PLAYING

01:52

CIDP Assessment Tools: Grip Strength

Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP

NOW PLAYING

14:01

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

NOW PLAYING

15:31

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

NOW PLAYING

9:35

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Discover the results of two recent clinical studies of IVIg treatments for CIDP.

Our Experts on CIDP

VIEW ALL EXPERTS

Jeffrey A. Allen, MD

University of Minnesota

Jeffrey A. Allen, MD

University of Minnesota

CIDP
MMN

Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

CIDP
MMN

Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

CIDP
GBS

Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan.

Van den Bergh, MD PhD

University Hospital Saint-Luc, Brussels, Belgium

Van den Bergh, MD PhD

University Hospital Saint-Luc, Brussels, Belgium

CIDP

Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?

What are the symptoms of CIDP?

How is CIDP treated?